---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-326083"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2026-07-30T20:01:15+00:00"
generated_at: "2026-07-30T20:02:16.393004+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B

## Summary
- Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.
- Adjusted EBITDA $8.0M vs -$5.6M; FY2026 revenue guidance raised to $1.595-1.605B.
- Signed ~$200M in new Data and Applications licenses; MRD volume 9,000 tests.
- Agreed to acquire Personalis for $16.25/share (~$1.5B enterprise value).
- FDA approved xT Tumor Only CDx assay; first lab with both tumor-only and tumor-normal CDx.

## SEC filing metadata
- accession: 0001193125-26-326083
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2026-07-30T20:01:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/0001193125-26-326083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/tem-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-326083
- JSON: https://secwatch.observer/filing/0001193125-26-326083.json
- Plain text: https://secwatch.observer/filing/0001193125-26-326083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.